Lv3
278 积分 2022-05-16 加入
FGFR rearrangements: oncogenic drivers and therapeutic targets
5天前
已关闭
Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?
1个月前
已完结
Negative Allosteric Modulators of A2AR: A New Weapon for Cancer Immunotherapy?
1个月前
已完结
Turning Off STAT6 with a Targeted Degrader
1个月前
已完结
MDM2 Degrader as a Promising Therapeutic Strategy for Cancer Treatment
1个月前
已完结
CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond
1个月前
已完结
Nasal delivery of secretory IgA confers enhanced neutralizing activity against Omicron variants compared to its IgG counterpart
1个月前
已完结
Lck is a key target of imatinib and dasatinib in T-cell activation
1个月前
已完结
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
1个月前
已完结
Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia
1个月前
已完结
皖公网安备34019202002308
